On March 19, 2026, the Board of AN2 Therapeutics, Inc. approved a stock option repricing of all outstanding Eligible Options under the 2017 and 2022 Equity Incentive Plans to $3.91 per share, including options held by named executive officers and non-employee directors. This provides retention incentives without stock dilution or additional cash costs.
Key takeaways
Option Repricing effective March 19, 2026, reducing exercise price to $3.91 per share for all Eligible Options prior to that date
Applies to stock options held by named executive officers and non-employee Board members
Eric Easom (President, CEO, Board chair): 742,649 Eligible Options, original prices $6.60-$17.28 per share
Joshua Eizen (Chief Legal Officer, COO): 142,150 Eligible Options, original prices $14.29-$17.88 per share
Lucy Day (CFO): 221,965 Eligible Options, original prices $6.60-$17.28 per share
Premium End Date is earliest of September 19, 2027, change in control, or holder's death/disability; early exercise requires original price payment